Clinigen Share Discussion Threads

[aishah] 19/12/2013 20:15

US buying I reckon. Also MSCI weightings kicking in as funds re-balance. Maybe some news due?
Very Strong Hold - run profits imo.

[dasv] 19/12/2013 14:56

even at this sp, not overvalued (PEG < 1)

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-14 140.94 24.15 23.31p 24.5 0.9 +26% 3.01p 0.5%

[scottishfield] 12/12/2013 10:16

resilient little fella this one.

[mymini] 04/12/2013 11:38

Found an interesting article with the ceo, albeit a few weeks old.

hxxp://www.thepharmaletter.com/article/interview-clinigen-s-ceo-peter-george-on-the-company-s-record-growth

[aishah] 21/11/2013 20:32

Added to the MSCI Global Small Cap index from 26th November. Also one of 22 AIM companies with a ten bagger potential in the IC game changers list. Expect a lot more following imo. dyor

[scottishfield] 21/11/2013 16:42

great close 515.

[gucci] 21/11/2013 15:20

:-( but cant justify the share price at these levels
think its going up on hot air
good luck nurdin

[nurdin] 21/11/2013 15:03

Still out Gucci? Looks like a major breakout is in the making ...

[gucci] 07/11/2013 17:47

Out for now

[gucci] 07/11/2013 17:46

Out for now

[nurdin] 07/11/2013 15:40

sure is now :o)

[gucci] 05/11/2013 13:56

taking off m:-)

[nurdin] 05/11/2013 13:41

Breaking out now...lovely to see :o)

[nurdin] 05/11/2013 10:57

ello ello...:o)

[nurdin] 30/10/2013 09:35

cheers cest :o)

[cestnous] 30/10/2013 09:31

From I.C. online


Clinigen
Clinigen Group PLC (CLIN:LSE)


Drug services firm Clinigen (CLIN) came to market just over a year ago with a rather unusual business model. However, maiden full-year results last month demonstrated to the market just how attractive this business model is proving to be and have helped add to the company's growing army of plaudits. The company has three businesses. It supplies drugs for global clinical trials for pharma clients, it also buys drugs that big pharma companies view as moribund and reinvigorates sales, and finally it provides drug consultation services.

There are cost synergies between Clinigen's three businesses but also, and perhaps most importantly, intellectual synergies, as the range of businesses provides Clinigen with in-depth knowledge about potential market niches and possible drug acquisition opportunities.

The view that the company has a business model that provides it with rather unique advantages was strengthened by the 29 per cent underlying EPS growth recently reported for the full year, which was almost all organic. With the consultancy business growing particularly strongly and new drugs on the roster for the coming year, there is a clear buzz about prospects.



Mkt Cap Price 3-mth momentum 6-mth momentum 1-yr momentum
£388m 470p 46.9% 85.8% 142.9%
Fwd PE* DY P/BV P/Tang BV Net cash/debt(-) EPS gr FY+1 EPS gr FY+2
27 0.6% 7.6 32 £11m 14% 21%
Last IC view: Buy, 435p, 25 Sep 2013

[nurdin] 23/10/2013 14:38

Not long to wait it seems :o)

[rampmeister] 17/10/2013 15:13

Another ath....yawn. These seem in a hurry to get to 5 quid.

RM

[cestnous] 08/10/2013 09:03

Bid is actually up on yesterday at the moment.

[cestnous] 07/10/2013 22:06

None at all

[sweetshoppe] 07/10/2013 21:17

Why the huge increase today? Any ideas anyone?

[nurdin] 07/10/2013 17:03

Perhaps it has come to the attention of other US Institutions? :o)

[leeson31] 07/10/2013 16:42

Jeez, this stock has no awareness of gravity. lol

im not in, missed it, but well done guys!